Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.


Journal

Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674

Informations de publication

Date de publication:
01 2022
Historique:
received: 27 07 2021
revised: 18 11 2021
accepted: 19 11 2021
pubmed: 7 12 2021
medline: 7 1 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

The emergence of SARS-CoV-2 virus has resulted in a worldwide pandemic, but effective antiviral therapies are not widely available. To improve treatment options, we conducted a high-throughput screen to uncover compounds that block SARS-CoV-2 infection. A minimally pathogenic human betacoronavirus (OC43) was used to infect physiologically-relevant human pulmonary fibroblasts (MRC5) to facilitate rapid antiviral discovery in a preclinical model. Comprehensive profiling was conducted on more than 600 compounds, with each compound arrayed across 10 dose points. Our screening revealed several FDA-approved agents that can attenuate both OC43 and SARS-CoV-2 viral replication, including lapatinib, doramapimod, and 17-AAG. Importantly, lapatinib inhibited SARS-CoV-2 RNA replication by over 50,000-fold. Further, both lapatinib and doramapimod could be combined with remdesivir to improve antiviral activity in cells. These findings reveal novel therapeutic avenues that could limit SARS-CoV-2 infection.

Identifiants

pubmed: 34871905
pii: S0042-6822(21)00233-6
doi: 10.1016/j.virol.2021.11.008
pmc: PMC8626825
pii:
doi:

Substances chimiques

Antiviral Agents 0
Benzoquinones 0
Drug Combinations 0
Lactams, Macrocyclic 0
Naphthalenes 0
Phenylurea Compounds 0
Pyrazoles 0
RNA, Viral 0
Lapatinib 0VUA21238F
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
tanespimycin 4GY0AVT3L4
doramapimod HO1A8B3YVV
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-68

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI050698
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127370
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM068411
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Cell Rep. 2021 Apr 6;35(1):108959
pubmed: 33811811
Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302
pubmed: 16597209
J Clin Oncol. 2005 Aug 10;23(23):5305-13
pubmed: 15955900
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Nat Struct Biol. 2002 Apr;9(4):268-72
pubmed: 11896401
Nature. 2003 Sep 25;425(6956):407-10
pubmed: 14508491
J Antimicrob Chemother. 2020 Oct 1;75(10):2977-2980
pubmed: 32607555
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Mol Cell. 2020 Jun 18;78(6):1096-1113.e8
pubmed: 32416067
Sci Signal. 2019 Oct 01;12(601):
pubmed: 31575731
PLoS Pathog. 2019 Jan 24;15(1):e1007569
pubmed: 30677091
PLoS One. 2015 Nov 16;10(11):e0142845
pubmed: 26571496
Pharmacotherapy. 2020 Jul;40(7):659-671
pubmed: 32446287
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
ACS Med Chem Lett. 2020 Oct 25;11(12):2526-2533
pubmed: 33324471
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Drugs. 2007;67(14):2101-8; discussion 2109-10
pubmed: 17883289
Cell Metab. 2019 May 7;29(5):1166-1181.e6
pubmed: 30799286
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573

Auteurs

M H Raymonda (MH)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

J H Ciesla (JH)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

M Monaghan (M)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

J Leach (J)

Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.

G Asantewaa (G)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

L A Smorodintsev-Schiller (LA)

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

M M Lutz (MM)

Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.

X L Schafer (XL)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

T Takimoto (T)

Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.

S Dewhurst (S)

Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA.

J Munger (J)

Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA; Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: joshua_munger@urmc.rochester.edu.

I S Harris (IS)

Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: isaac_harris@urmc.rochester.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH